

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENOR BIOPHARMA HOLDINGS LIMITED

嘉和生物藥業(開曼)控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

(1) RESIGNATION OF CHAIRMAN OF THE BOARD AND EXECUTIVE DIRECTOR AND (2) APPOINTMENT OF EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER

RESIGNATION OF CHAIRMAN OF THE BOARD AND EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of Genor Biopharma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Dr. Guo Feng (“**Dr. Guo**”) has tendered his resignation as the chairman of the Board and an executive Director due to his decision to devote more time on his other business commitments, with effect from 12 September 2024. Dr. Guo will remain as the chief executive officer of the Company.

Dr. Guo has confirmed that (i) he has no claim against the Company in respect of his resignation; (ii) there is no disagreement between him and the Board; and (iii) there are no matters that need to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company (the “**Shareholders**”) in relation to his resignation.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Guo for his valuable contribution to the Company during his tenure of office as the chairman of the Board and an Executive Director.

APPOINTMENT OF EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER

The Board is pleased to announce that Mr. Weng Chengyi (“**Mr. Weng**”) is appointed as an executive Director and the chief financial officer of the Company (“**Chief Financial Officer**”) with effect from 12 September 2024.

The biographical details of Mr. Weng are set out below:

Mr. Weng, aged 44, is currently the secretary of the Board and the Vice President of Finance of the Company. Mr. Weng has served as the assistant manager at Deloitte Touche Tohmatsu CPA Limited for approximately 7 years. Mr. Weng also has more than 11 years of experience serving as finance manager and finance director at various listed companies. Since November 2018, Mr. Weng has been serving as the secretary of the Board and the Vice President of Finance of the Company.

Mr. Weng holds a Degree of Bachelor of Business Administration from the Fu Jen Catholic University.

Mr. Weng has entered into a service agreement as an executive Director with the Company for an initial term of three years with effect from 12 September 2024, and renewable automatically thereafter for successive periods of three years until terminated by giving to the other party no less than three months prior notice in writing. Pursuant to the service agreement, Mr. Weng is subject to retirement by rotation and re-election in accordance with the articles of association of the Company. Mr. Weng is entitled to the remuneration package of emoluments including an annual salary of RMB1,105,452, together with discretionary bonuses and other incentive and subsidies payable by the Group to Mr. Weng, as determined by the Board and in accordance with the Company's policy. The remuneration of Mr. Weng will be subject to annual review by the remuneration committee of the Board and the Board from time to time with reference to his responsibilities, work experience, qualification, the Company's remuneration policy and the prevailing market conditions.

As at the date of this announcement, Mr. Weng is interested in 1,530,000 shares of the Company (the "Shares"), representing approximately 0.29% of the total number of issued Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO"). Save as disclosed herein, Mr. Weng does not have any interest in or is deemed to be interested in any Shares, underlying Shares or debentures of the Company or its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, as at the date of this announcement, Mr. Weng has confirmed to the Board that he (i) did not hold any directorships in any public companies the securities of which are listed on any securities market in Hong Kong and overseas in the past three years, nor any other major appointments or professional qualifications; (ii) does not hold any other positions in the Company and other members of the Group; and (iii) is not related to any directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, there is no other information relating to the appointment of Mr. Weng that is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules nor any matter that needs to be brought to the attention of the Shareholders or the Stock Exchange.

The Board would like to extend a warm welcome to Mr. Weng on his appointment.

By Order of the Board
Genor Biopharma Holdings Limited
Mr. Weng Chengyi
Executive Director and Chief Financial Officer

Hong Kong, 12 September 2024

As at the date of this announcement and following the above resignation and appointment of Directors, the Board comprises Mr. WENG Chengyi (Chief Financial Officer) as an executive Director; Dr. LYU Dong, Mr. YU Tieming and Mr. LIU Yi as non-executive Directors; and Mr. ZHOU Honghao, Mr. FUNG Edwin and Mr. CHEN Wen as independent non-executive Directors.